{"id":"NCT02187159","sponsor":"Daiichi Sankyo","briefTitle":"Treatment of Pain Associated With Fibromyalgia","officialTitle":"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2016-07-07","completion":"2016-07-07","firstPosted":"2014-07-10","resultsPosted":"2020-11-09","lastUpdate":"2020-11-09"},"enrollment":1270,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain Associated With Fibromyalgia"],"interventions":[{"type":"DRUG","name":"DS-5565","otherNames":["mirogabalin"]},{"type":"DRUG","name":"Pregabalin","otherNames":["Lyrica"]},{"type":"DRUG","name":"Placebo tablet","otherNames":["Placebo matching DS-5565"]},{"type":"DRUG","name":"Placebo capsule","otherNames":["Placebo matching pregabalin"]}],"arms":[{"label":"DS-5565 QD","type":"EXPERIMENTAL"},{"label":"DS-5565 BID","type":"EXPERIMENTAL"},{"label":"Pregabalin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.","primaryOutcome":{"measure":"Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo","timeFrame":"Baseline up to Week 13 postdose","effectByArm":[{"arm":"Placebo","deltaMin":-1.86,"sd":0.13},{"arm":"Pregabalin 150 mg BID","deltaMin":-2.47,"sd":0.133},{"arm":"DS-5565 15 mg QD","deltaMin":-2.24,"sd":0.133},{"arm":"DS-5565 15 mg BID","deltaMin":-2.09,"sd":0.134}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0008"},{"comp":"OG000 vs OG002","p":"0.0392"},{"comp":"OG000 vs OG003","p":"0.2192"},{"comp":"OG001 vs OG002","p":"0.2095"},{"comp":"OG001 vs OG003","p":"0.0381"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":176,"countries":["United States","Australia","Bulgaria","Estonia","Hungary","India","Latvia","New Zealand","Romania","Russia","Slovakia","United Kingdom"]},"refs":{"pmids":["31284771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":315},"commonTop":["Headache","Dizziness","Drug withdrawal syndrome","Weight increased","Somnolence"]}}